Vaccination of Triple Negative Breast Cancer Patients
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in
combination with standard neoadjuvant chemotherapy and surgery in patients with clinical
stage I, II or III triple negative breast cancer (TNBC). This study will compare the vaccine
plus standard neoadjuvant chemotherapy and surgery to standard neoadjuvant chemotherapy and
surgery alone.